This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Vora, J. Articles by Weston, C. Search for Related Content Social Bookmarking                         What's this?

BENEDICT: primary prevention of microalbuminuria in hypertensive type 2 diabetes

Bergamo NEphrologic Diabetes Complication Trial (BENEDICT)

Royal Liverpool University Hospitals, Link 7C, Prescot Street, Liverpool, L7 8XP, UK, jiten.vora{at}rlbuht.nhs.uk

Clive Weston

Singleton Hospital, Sketty, Swansea, SA2 8QA, UK

Key Words: type 2 diabetes • microalbuminuria • nephropathy • hypertension • trandolapril.

References

• Ruggenenti P., Fassi A., Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-51.[Abstract/Free Full Text]
• Wild S., Roglic G., Green A. et al. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27: 1047-53.[Abstract/Free Full Text]
• Adler AI, Stevens RJ, Manley SE et al. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney International 2003;63:225-32.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• The Royal College of General Practitioners Effective Clinical Practice Unit. Guideline entitled `Diabetic renal disease: prevention and early management.' 2002 Accessed at: http://www.nice.org.uk/page.aspx?o=39385
• Marshall SM Review. Recent advances in diabetic nephropathy. Postgrad Med J 2004;80:624-33.[Abstract/Free Full Text]
• de Zeeuw D. Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment? Kidney Int Suppl 2004;92:S2-S6.[Medline] [Order article via Infotrieve]
• Parving H-H., Lehnert H., Brochner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.[Abstract/Free Full Text]
• Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:53-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.[Abstract/Free Full Text]
• Continued on page 88
• Continued from page 86
• Brenner BM, Cooper ME, de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.[Abstract/Free Full Text]
• Bakris GL, Weir MR, De Quattro V. et al. Effects of ACE inhibitor/calcium channel antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1996;50:1641-50.[Web of Science][Medline] [Order article via Infotrieve]
• de Zeeuw D., Remuzzi G., Parving H-H. et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004;110:921-7.[Abstract/Free Full Text]
• Furtner M., Kiechl S., Mair A. et al. Urinary albumin excretion is independently associated with carotid and femoral atherosclerosis in the general population. Euro Heart J 2005;26:279-87.[Abstract/Free Full Text]
• Ravid M., Brosh D., Levi Z. et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. Annals Int Med 1998;128:982-8.[Abstract/Free Full Text]
• 5. The EUCLID study group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;349:1787-92.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Strippoli GFM, Craig M., Deeks JJ et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004;329:828-31.[Abstract/Free Full Text]
• So WY, Ozaki R., Chan NN et al. Effect of angiotensin-converting enzyme inhibition on survival in 3,773 Chinese type 2 diabetic patients. Hypertension 2004;44:294-9.[Abstract/Free Full Text]
• NICE. Inherited guideline H, 2002. Management of type 2 diabetes - management of blood pressure and blood lipids. Accessed at: http://www.nice.org.uk/page.aspx?o=38551

The British Journal of Diabetes & Vascular Disease, Vol. 6, No. 2, 84-88 (2006)
DOI: 10.1177/14746514060060020601


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Vora, J. Articles by Weston, C. Search for Related Content Social Bookmarking                         What's this?